ROCKETING HIGHER: SpaceX continues to climb post-IPO

Key Concepts

• SpaceX Valuation: Analysis of SpaceX’s market potential, focusing on Starlink and compute infrastructure.
• Hyper-scalers: Large-scale cloud computing providers; SpaceX is noted for unseating Oracle in this sector.
• Fourth Industrial Revolution: The current era of rapid technological advancement driven by AI and automation.
• GLP-1 Agonists: A class of medications (e.g., for weight loss) compared to AI in terms of consumer value and market impact.
• Proprietary Data/IP: The essential requirement for businesses to maintain a competitive advantage as AI intelligence becomes commoditized.
• Forward Earnings Multiples: A valuation metric used to determine if a stock is trading at a discount relative to its historical performance.

---

1. The SpaceX Investment Thesis

The discussion centers on the aggressive valuation of SpaceX, which some critics argue is inflated at 300x earnings. Ted Thatcher (Bright Light Wealth) argues that this critique ignores the denominator effect—the rapid growth rate of the company.

• Revenue Projections: Goldman Sachs and Morgan Stanley project revenue to grow from $60 billion to $110 billion (adjusted) within two years.
• Valuation: Even if growth targets are missed, the company is viewed as having significant upside toward a $2 trillion valuation.
• Business Drivers:
  • Starlink: Projected to hit $144 billion in revenue by 2032.
  • Compute Business: SpaceX has recently moved into the top four hyper-scalers, surpassing Oracle.
  • Diversification: The business model is described as five-fold, including terrestrial data centers and orbital space centers, alongside launch services and Starship (viewed as a "call option" on the stock).

2. Market Strategy and NVIDIA

The conversation shifts to NVIDIA, which is currently trading near its lowest multiple in 10 years (approx. 20x forward earnings, with a 10-year low of 18x).

• Investment Perspective: Despite being the world's largest company, hedge funds are betting against it, which Thatcher views as a miscalculation.
• Price Target: Thatcher sets an $800 target for NVIDIA, noting that it requires a 2–3 year time horizon.
• Catalysts: The primary tailwind is the build-out of data centers. Thatcher highlights Jensen Huang’s (NVIDIA CEO) assertion that Meta is currently the leader in monetizing AI.

3. The "Token Economy" vs. "Human Economy"

A sophisticated argument is presented regarding the future of AI-driven business models:

• The Thesis: If a company lacks proprietary data and intellectual property (IP) to iterate on, it will fail as "intelligence" becomes a commoditized utility.
• Strategic Question: Firms must identify where they sit in the "value stack" of frontier models. Without unique data, businesses will struggle to survive in a world where AI capabilities are ubiquitous.

4. GLP-1s and Consumer Value

The discussion compares the impact of GLP-1 weight-loss drugs to the AI revolution.

• Tug-of-War: While Eli Lilly has seen a massive run-up, investors are cautioned to be thoughtful regarding entry points and position sizing.
• Comparative Value: Thatcher poses a hypothetical choice to consumers: "Would you rather give up your GLP-1 or your ChatGPT subscription?"
• Future Outlook: The technology is in the "early innings," with GLP-2 and GLP-3 iterations on the horizon, suggesting the potential for these drugs extends far beyond current weight-loss applications.

---

Synthesis and Conclusion

The overarching theme is that Wall Street is currently struggling to value the "Fourth Industrial Revolution" because it relies on narrow, traditional metrics that fail to capture the speed of AI-driven growth.

Main Takeaways:

1. SpaceX is undervalued by traditional metrics because analysts underestimate the scale of its compute and connectivity (Starlink) businesses.
2. NVIDIA represents a value opportunity, trading at historically low multiples despite its central role in the AI infrastructure build-out.
3. Business Sustainability in the AI era depends entirely on proprietary data; without it, companies will be commoditized.
4. Healthcare Innovation (GLP-1s) is viewed as a "miracle" category that, like AI, is only in its infancy, offering significant long-term value creation for consumers and investors alike.